A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

Inclusion Criteria: * Healthy males * Aged between 30 and 55 years of age, inclusive * Body mass index of 18.0 to 35.0 kg/m2, inclusive, or, if outside the range, considered not clinically significant by the investigator and the medical monitor * Must be willing and able to communicate and participate in the whole study * Must have regular daily bowel movements * Must provide written informed consent * Must agree to use an adequate method of contraception Exclusion Criteria: * Subjects who have received any IMP in a clinical research study within the previous 3 months * Subjects who are study site or sponsor employees, or immediate family members of a study site or sponsor employee * Subjects who have previously been enrolled in this study * History of any drug or alcohol abuse in the past 2 years * Regular alcohol consumption \>21 units per week * Current smokers and those who have smoked within the last 12 months * Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months * Radiation exposure. No occupationally exposed worker, as defined in the Ionising Radiation Regulations 1999, shall participate in the study * Subjects who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at screening * Abnormal liver function as assessed by clinical chemistry * Positive drugs of abuse test result * Positive HBsAg, HCV Ab or HIV results * Evidence of renal impairment at screening * History of clinically significant cardiovascular, renal, hepatic, chronic respiratory, neurological, dermatological or GI disease, or psychiatric disorder, as judged by the investigator * Any abnormality of ECG parameters * Any abnormality of cardiac rhythm or history thereof * Serious adverse reaction or serious hypersensitivity to any drug or the formulation excipients * Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hayfever is allowed, unless it is active at screening or admission * Donation or loss of greater than 400 mL of blood within the previous 3 months * Subjects who are taking, or have taken, any prescribed or over-the-counter drug or herbal or any other 'alternative' remedies in the 14 days before IMP administration * Failure to satisfy the investigator of fitness to participate for any other reason